Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Jet2 summer seat capacity rises 12.4pc

(Sharecast News) - Airline business Jet2 said on Thursday that summer 2024 on-sale seat capacity was 12.4% higher than Summer 2023 at 17.17m, a "slight increase" on the level reported at its preliminary results. Jet2 said July and August experienced "strong" late booking momentum, with September currently showing a similar trend. As a result, average load factor was now 1.2% behind Summer 2023 at the same point. Booked-to-date package holiday customers were up by 8%, representing 70.2% of total departing passengers, with flight-only passengers increasing by 17%.

The London-listed group also said Winter 2024/25 forward bookings were "encouraging", with average load factor 0.8% ahead of Winter 2023/24 at the same time 12 months earlier, against a 15.0% seat capacity increase to 5.14m seats.

"Year to date the business continues to trade in line with management's expectations. However, given the late booking profile, the remaining summer months of September and October not yet complete, plus the majority of Winter 2024/25 seat capacity still to sell, it remains premature to provide definitive guidance as to group profitability for the financial year ending 31 March 2025. Consequently, we will provide a further update at the interim results on 21 November 2024," said Jet2

As of 0950 BST, Jet2 shares were up 1.31% at 1,474.0p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

Berenberg lowers target price on Impax Asset Management
(Sharecast News) - Analysts at Berenberg lowered their target price on Impax Asset Management from 620.0p to 560.0p on Tuesday but noted that outflows had started to slow.
GSK's Arexvy provides protection over three RSV seasons, trial shows
(Sharecast News) - GSK has announced positive results from a phase III trial of its Arexvy RSV vaccine, showing that just one dose of the treatment could help protect older adults at risk of RSV disease over three seasons.
S&U revenue up, profitability a challenge in first half
(Sharecast News) - Motor and property finance specialist S&U reported a mixed first-half financial performance on Tuesday, after group revenue increased 9% year-on-year to £60.4m.
Loungers reports slight slowdown in LFL sales growth
(Sharecast News) - Cosy Club owner Loungers reported a slight slowdown in like-for-like sales growth on Tuesday and a jump in revenue.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.